What are the recommended treatment strategies for avoidant/restrictive food intake disorder (ARFID)?

Treatment Recommendations for ARFID

While the 2023 APA Eating Disorders Practice Guideline does not provide specific treatment recommendations for ARFID, the evidence supports a multidisciplinary approach centered on eating disorder-focused psychotherapy, with cognitive-behavioral therapy (CBT) adaptations showing the most promise.

Critical Gap in Current Guidelines

The most recent APA guideline 1 provides comprehensive recommendations for anorexia nervosa, bulimia nervosa, and binge-eating disorder, but notably omits specific treatment protocols for ARFID. This represents a significant limitation given ARFID's distinct pathophysiology and treatment needs compared to other eating disorders.

Evidence-Based Treatment Approach

Primary Treatment: Psychological Interventions

Based on the strongest available evidence, adapted cognitive-behavioral therapy (CBT) is the most promising psychological intervention for ARFID 2. A 2026 meta-analysis demonstrated that psychological therapies for adolescents and adults with ARFID produce:

• Medium-size reductions in ARFID psychopathology (effect size g = 0.63, p < 0.001)
• Large increases in weight (effect size g = 1.26, p < 0.001)
• Medium-size reductions in anxiety (effect size g = 0.42, p < 0.001)
• Small reductions in depression (effect size g = 0.34, p < 0.05) 3

Age-Specific Considerations

For children and adolescents with involved caregivers:

• Family-based treatment (FBT) with ARFID-specific modifications should be the first-line approach 4, 5
• Parental psychoeducation is paramount, as effective ARFID interventions are often counter-intuitive to parents 4
• Treatment must gain parental trust and cooperation early

For adults or those without involved caregivers:

• Individual eating disorder-focused CBT adapted for ARFID presentations 2
• Exposure therapy targeting specific food avoidance patterns 4

Treatment Framework

1. Initial Assessment Requirements

Following general eating disorder assessment principles 1:

• Vital signs: Temperature, resting heart rate, blood pressure, orthostatic measurements
• Anthropometrics: Height, weight, BMI (or age-adjusted percentiles for pediatrics)
• Laboratory workup: CBC, comprehensive metabolic panel (electrolytes, liver enzymes, renal function)
• ECG: Mandatory in restrictive eating presentations 1
• Detailed food history: Breadth of food variety, patterns of food group elimination, sensory sensitivities
• Co-occurring conditions: Screen for autism spectrum disorder, anxiety disorders, sensory processing disorders, and neurodevelopmental conditions 5, 6

2. Multidisciplinary Team Composition

Essential team members 1:

• Psychiatrist or psychologist (primary therapist)
• Registered dietitian with eating disorder expertise
• Primary care physician or pediatrician
• Occupational therapist (for sensory processing issues)

3. Treatment Intensity Algorithm

Outpatient treatment when:

• Medically stable vital signs
• Weight >85% expected body weight
• Adequate oral intake to prevent further decline

Higher level of care (partial hospitalization/inpatient) when 7:

• Medical instability (bradycardia, hypotension, electrolyte abnormalities)
• Acute weight loss requiring nutritional rehabilitation
• Complete refusal of oral intake
• Dependence on enteral feeding requiring weaning
• Acute triggering event (88% of inpatient ARFID cases have preceding acute events) 7

4. Specific Treatment Components

Behavioral interventions 7:

• Individualized based on ARFID presentation (sensory sensitivity vs. lack of interest vs. fear-based avoidance)
• Systematic desensitization and exposure to avoided foods
• Contingency management for increasing food variety
• Interoceptive awareness training for hunger/satiety cues

Neurodevelopmental accommodations 5:

• Executive functioning supports (visual schedules, structured meal planning)
• Sensory processing modifications (texture progression, environmental controls)
• Dialectical Behavior Therapy (DBT) skills for emotion regulation during exposure 5

5. Nutritional Rehabilitation

When weight restoration is needed:

• Set individualized weekly weight gain goals (similar to anorexia nervosa protocols) 1
• Enteral feeding may be necessary initially but should be systematically weaned as oral intake increases 7
• 92% of inpatient ARFID patients who completed treatment achieved 100% oral nutrition 7

Pharmacotherapy

No FDA-approved medications exist for ARFID 2. Unlike bulimia nervosa (fluoxetine) or binge-eating disorder (lisdexamfetamine), there is no evidence-based pharmacological treatment for ARFID specifically.

Consider medication only for:

• Co-occurring anxiety disorders (may facilitate exposure therapy)
• Co-occurring depression
• Autism spectrum disorder symptoms interfering with treatment

Critical Pitfalls to Avoid

1. Do not apply anorexia nervosa treatment protocols directly - ARFID lacks body image disturbance and requires different psychological interventions
2. Do not overlook neurodevelopmental comorbidities - 75% of inpatient ARFID cases have psychiatric diagnoses 7; autism spectrum disorder is particularly common 6
3. Do not delay higher level of care - Acute triggering events often precipitate severe restriction requiring intensive intervention 7
4. Do not ignore sensory processing needs - Sensory hypersensitivity is a core etiological factor requiring specific accommodations 4

Evidence Quality Caveat

The current evidence base for ARFID treatment is limited 3. The 2026 meta-analysis notes that most studies are case reports and case series, with very few randomized controlled trials. The promising outcomes must be interpreted cautiously given this methodological limitation. However, the consistency of positive results across multiple domains (weight, psychopathology, anxiety) supports the current treatment approach until higher-quality evidence emerges.

Follow-Up and Monitoring

• Track dietary variety expansion as a primary outcome measure
• Monitor weight trajectory weekly during active treatment
• Reassess ARFID symptoms at regular intervals, as prevalence can fluctuate over time (17-19% at different timepoints) 8
• Sustained progress has been documented for several months post-discharge in inpatient cohorts 7